|ID:224 ||Flecainide||Search Links: General Info : Protocols : Patient Info|
|Description||Cardiac anti-arrhythmic drug. For monitoring purposes, blood should not be drawn until a steady state has been attained.|
|Indication||Therapeutic drug monitoring (TDM) of anti-arrhythmic drugs|
|Additional Info||Used for treatment of AV nodal reciprocating tachycardia. Normal dose in adults is 200-400 mg/day. Excreted unchanged in urine.
|Interpretation||Half life is 14 hours, 20 hours if have ventricular arrhythmias. Steady state plasma levels achieved after 3-5 days of treatment.
|Ref. Range (Male)||0.15 - 0.9 |
|Ref. Range (Female)||0.15 - 0.9|
|Ref. Range (Paed)|| |
|Ref. Range Notes|| |
|IP Acute TAT||- Contact Laboratory|
|IP Routine TAT||At least 1 week|
|GP Acute TAT||- Contact Laboratory|
|GP Routine TAT||At least 1 week|
|Turnround Comment||Robert Haddon:HutchingsAD@cardiff.ac.uk|
Originally edited by : JHB. Last edited on 22/11/2018 12:04:46. Published By on 22/11/2017 12:04:46.